AU2009290365B2 - Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers - Google Patents

Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers Download PDF

Info

Publication number
AU2009290365B2
AU2009290365B2 AU2009290365A AU2009290365A AU2009290365B2 AU 2009290365 B2 AU2009290365 B2 AU 2009290365B2 AU 2009290365 A AU2009290365 A AU 2009290365A AU 2009290365 A AU2009290365 A AU 2009290365A AU 2009290365 B2 AU2009290365 B2 AU 2009290365B2
Authority
AU
Australia
Prior art keywords
compound
dimethylamino
formula
diazenyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009290365A
Other languages
English (en)
Other versions
AU2009290365A1 (en
Inventor
Kiran Bhupathiraju
Ganga Raju Gokaraju
Rama Raju Gokaraju
Trimurtulu Golakoti
Sudhakar Kasina
Krishanu Sengupta
Venkateswarlu Somepalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kasina Laila Innova Pharmaceuticals Pvt Ltd
Original Assignee
Kasina Laila Innova Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Pvt Ltd filed Critical Kasina Laila Innova Pharmaceuticals Pvt Ltd
Publication of AU2009290365A1 publication Critical patent/AU2009290365A1/en
Application granted granted Critical
Publication of AU2009290365B2 publication Critical patent/AU2009290365B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009290365A 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers Ceased AU2009290365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
IN2230/CHE/08 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (2)

Publication Number Publication Date
AU2009290365A1 AU2009290365A1 (en) 2010-03-18
AU2009290365B2 true AU2009290365B2 (en) 2014-08-14

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009290365A Ceased AU2009290365B2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8258119B2 (enExample)
EP (1) EP2324006B1 (enExample)
JP (1) JP2012502900A (enExample)
KR (1) KR20110063537A (enExample)
CN (1) CN102149703B (enExample)
AU (1) AU2009290365B2 (enExample)
BR (1) BRPI0913485A2 (enExample)
CA (1) CA2736732A1 (enExample)
IL (1) IL211366A0 (enExample)
NZ (1) NZ591394A (enExample)
WO (1) WO2010029577A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006651A2 (pt) * 2009-04-27 2015-08-25 Kasina Laila Innova Pharmaceuticals Private Ltd Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
DE112014006766T5 (de) * 2014-06-27 2017-04-27 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Herstellung und medizinische Verwendung von Triazenen
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
KR20180008594A (ko) 2015-05-18 2018-01-24 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 및 그의 용도
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
EP3297440A4 (en) * 2015-06-19 2019-04-10 Syn-Nat Products Enterprise LLC COMPOSITION WITH CARBOPLATIN AND USE
KR20180021805A (ko) 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 조성물 및 이의 용도
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) * 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS RN 785838-51-9, STN Entry date 2004 *
CAS RN 879853-02-8, STN Entry date 2006 *
Fulmer and O'Dell, J. of Pharmaceutical Sciences, 1971, 60(4), 554-560 *
Henriksen and Autrup, Acta Chem. Scand., 1972, 26(8), 3342-3346 *
Lowe et al, J. Med. Chem., 1992, 35, 3377-3382 *
Wagner et al, Polish J. Chem., 2003, 77, 1001-1006 *

Also Published As

Publication number Publication date
US20100068178A1 (en) 2010-03-18
IL211366A0 (en) 2011-04-28
CN102149703A (zh) 2011-08-10
JP2012502900A (ja) 2012-02-02
CA2736732A1 (en) 2010-03-18
KR20110063537A (ko) 2011-06-10
CN102149703B (zh) 2014-09-10
EP2324006B1 (en) 2014-08-13
WO2010029577A2 (en) 2010-03-18
WO2010029577A3 (en) 2010-05-06
BRPI0913485A2 (pt) 2016-06-07
US8258119B2 (en) 2012-09-04
EP2324006A2 (en) 2011-05-25
NZ591394A (en) 2013-03-28
AU2009290365A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
US8258119B2 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
AU2010243213B2 (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
US9562060B2 (en) Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
JP2021503013A (ja) Ａｃｓｓ２阻害剤およびその使用方法
CZ124099A3 (cs) Derivát amidu aminothiofenkarboxylové kyseliny, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
WO2023212599A2 (en) Compounds and methods for targeted degradation of estrogen receptors
WO2019101171A1 (zh) 噻吩并环类化合物及其合成方法和应用
CN114080389A (zh) Nrf2活性化化合物
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
KR20210123314A (ko) 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용
JP5186566B2 (ja) ジチオロピロロン化合物類、それらの調製及び使用
US9278958B2 (en) Anti-cancer compounds
CN117986202B (zh) 具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用
EP4506346A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
IL271035B (en) Compounds useful in inhibiting human factor 3 trefoil
EP4705304A1 (en) Amido pyrido[3,4-b]indole-1, 4-dione compounds for treatment of porphyrias
KR20020027652A (ko) 아민 유도체
CN121591767A (zh) 一种含有碳硼烷的化合物及其用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAMES OF THE INVENTORS TO READ GOKARAJU, GANGA RAJU; KASINA, SUDHAKAR; GOKARAJU, RAMA RAJU; GOLAKOTI, TRIMURTULU; SOMEPALLI, VENKATESWARLU; SENGUPTA, KRISHANU AND BHUPATHIRAJU, KIRAN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired